A JAMA Study Just Tripled the Repeat-Overdose Risk Estimate. The First 30 Days After ED Discharge Are the Inflection Point.
Among 28,500 opioid-overdose survivors, 9% died and 21% had a repeat overdose within one year — roughly triple the prior literature estimate.
A JAMA Study Just Tripled the Repeat-Overdose Risk Estimate. The First 30 Days After ED Discharge Are the Inflection Point.
A new JAMA-published study of nearly 28,500 emergency-department-treated opioid-overdose survivors in Ontario between 2017 and 2023 found that 9% died and 21% experienced a repeat overdose within one year of discharge. The highest-risk window was the first 30 days, during which 2% of survivors died and 6% had a repeat overdose. The mortality rates are roughly three times higher than what earlier literature suggested — most of which was collected before fentanyl saturated the unregulated drug supply.
The clinical implication is direct: the moment an opioid-overdose survivor leaves the emergency department is the single highest-leverage handoff point in the entire SUD care pathway. The intervention bundle the study’s authors call for — guaranteed take-home naloxone, active warm handoff to medications for opioid use disorder (MOUD), and same-week peer follow-up — costs less per saved life than almost any other addiction intervention in the literature.
Why this matters for people in recovery
If you or someone you love is leaving an ED after an overdose: ask for a naloxone kit at discharge (most U.S. hospitals can provide one); ask whether the hospital can initiate buprenorphine on-site (most can, and the 24-hour window after an overdose is when this works best); and connect with a peer recovery coach or community navigation service before you leave the parking lot. The first 30 days are not the moment to wait for an appointment four weeks from Tuesday.
If you are in Arizona and looking for an ED-to-treatment connection that doesn’t fall through the cracks, Rize can help.
988 Suicide & Crisis Lifeline: Call or text 988. SAMHSA National Helpline: 1-800-662-HELP (4357) — free, confidential, 24/7.
Sources Cited
- 01.B
- 02.B
- 03.B
Filed Under
sciencebiologytreatment
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Dispensary Weed Is a Different Drug Than the One D.A.R.E. Warned You About
Dispensary THC now routinely exceeds 40%, quadruple 1995 levels. The addiction and psychosis science on high-potency cannabis is real, dose-dependent, and almost nobody at the counter has to mention it.
Science & MedicineThe Overdose Charts Miss This: A Decade of Data Says a Third of Alcohol-Induced Crises Come With Depression Attached
A decade of federal treatment data finds alcohol- and substance-induced psychiatric disorders are rare in raw numbers but frequently paired with depression — a screening gap most facilities aren't built to catch.
Science & MedicineEvery Two Years, the Fake Xanax Gets a New Name. The Real Trend Is the Naming Pattern Itself.
Bromazolam is the fourth designer benzodiazepine sold as counterfeit Xanax since 2020. The DEA keeps scheduling the newest one — the trend data says that's not where the problem lives.